With European Union (EU) membership providing much of the scientific, regulatory and trade infrastructure for the pharmaceutical industry, the UK EU Life Sciences Transition Programme was established by Government to ensure that the sector was in as strong a position as possible as the UK establishes a new relationship with the Europe and the rest of the world.
The work of the Programme and its Steering Group to date has been to establish consensus on the issues influencing the maintenance and growth of a world-leading Life Sciences environment in the UK outside of the EU.
Following the result of the EU referendum, in July 2016 Life Sciences Minister, George Freeman announced
that a UK EU Life Sciences
Transition Programme would be established between industry and Government. The Programme is supported by a Steering Group co-chaired by GlaxoSmithKline's Chief Executive Sir Andrew Witty, and AstraZeneca's Chief Executive Pascal Soriot. ABPI and the
BioIndustry Association (BIA) are also core members of this group, alongside the Association of the British Healthcare Industry (ABHI) and the British In Vitro Diagnostics Association (BIVDA).
The key objective of the Programme is to determine how to create a world-leading life sciences environment in the UK outside of the EU. This includes:
The Steering Group first reported the work of the Programme to the
Ministerial Industry Strategy Group (MISG) in September 2016. At this meeting, an initial report mapping out the issues influencing the sector was discussed
in the context of how to maintain and grow the Life Sciences industry in the UK outside of the EU.
The second meeting took place in November 2016 and focused on the progress made under each workstream of the Transition Programme. This work continues and will feed in to the Government's work on refreshing the life sciences industrial strategy.
For further information, please contact the
ABPI Press Office.